New treatment strategy tested for aggressive blood cancer
NCT ID NCT02858804
Summary
This study tested two different chemotherapy combinations, with or without the drug rituximab, for younger patients (age 65 or younger) newly diagnosed with mantle cell lymphoma. After initial treatment, patients received up to two years of maintenance therapy to help keep the cancer from returning. The goal was to find the most effective approach to control this type of blood cancer over the long term.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.